Department of Obstetrics and Gynecology, Georgia Cancer Center, 1120 15th Street, Augusta University, Augusta, GA, 30912, USA.
Department of Medicine, Indiana University School of Medicine, Van Nuys Medical Science Building, Suite 224, 635 Barnhill Drive, Indianapolis, IN 46202, USA.
Papillomavirus Res. 2020 Dec;10:100202. doi: 10.1016/j.pvr.2020.100202. Epub 2020 May 25.
The natural history of human papillomavirus (HPV) infection has been studied extensively in young women; this study investigated HPV infection in adult women.
Data from 3817 women aged 24-45 years in a global trial of the 4-valent HPV (6/11/16/18) vaccine were used to calculate prevalence of anogenital infections containing 9-valent (9v) HPV vaccine types (6/11/16/18/31/33/45/52/58) and five non-vaccine types (35/39/51/56/59). Incidence of infections and persistent infections was estimated for 989 placebo recipients naive to all 14 HPV types at baseline. Age-adjusted hazard ratios were calculated for various sociodemographic factors.
Prevalence of anogenital infection was highest in France at 29.2% (9vHPV types) and 21.7% (non-vaccine types) and lowest in the Philippines at 7.6% (9vHPV types) and 5.1% (non-vaccine types). Overall, HPV incidence (per 100 person-years) was 5.2 (9vHPV types) and 4.7 (non-vaccine types), and incidence of persistent infection was 2.7 (9vHPV types) and 2.1 (non-vaccine types). Factors associated with new HPV infections included younger age, younger age at first intercourse, being single, current use of tobacco, and higher number of past and recent sex partners.
Because mid-adult women acquire new HPV infections, administration of the 9vHPV vaccine could reduce HPV-related morbidity and mortality in this population.
人乳头瘤病毒（HPV）感染的自然史在年轻女性中已得到广泛研究；本研究调查了成年女性的 HPV 感染情况。
本研究使用了一项全球四价 HPV（6/11/16/18）疫苗试验中 3817 名 24-45 岁女性的数据，以计算包含九价（9v）HPV 疫苗型（6/11/16/18/31/33/45/52/58）和五种非疫苗型（35/39/51/56/59）的肛门生殖器感染的流行率。对 989 名在基线时对所有 14 种 HPV 型均无感染史的安慰剂组妇女，估计了感染和持续性感染的发生率。计算了各种社会人口统计学因素的年龄调整危险比。
法国的肛门生殖器感染流行率最高，9vHPV 型为 29.2%，非疫苗型为 21.7%；菲律宾的流行率最低，9vHPV 型为 7.6%，非疫苗型为 5.1%。总体而言，HPV 发病率（每 100 人年）为 5.2（9vHPV 型）和 4.7（非疫苗型），持续性感染的发病率为 2.7（9vHPV 型）和 2.1（非疫苗型）。与新 HPV 感染相关的因素包括年龄较小、初次性行为年龄较小、单身、当前吸烟、过去和最近性伴侣数量较多。
由于中年女性会获得新的 HPV 感染，因此在该人群中使用九价 HPV 疫苗可以降低 HPV 相关发病率和死亡率。
